Skip to search formSkip to main contentSkip to account menu

PRX 00023

Known as: PRX-00023, PRX00023 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

naluzotan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety
2008
2008
Effects of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist on Measures of Anxiety and Depression in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled Trial
PRX-00023, a serotonin 1A receptor agonist, was designed to provide high potency and selectivity for its target. To assess the… 
2008
2008
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
2007
2007
Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.
: EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist… 
2007
2007
Tolerability, Pharmacokinetics, and Neuroendocrine Effects of PRX‐00023, a Novel 5‐HT1A Agonist, in Healthy Subjects
PRX‐00023 is a novel, nonazapirone 5‐HT1A agonist in clinical development for treatment of affective disorders. The objectives of… 
Review
2007
Review
2007
Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.
  • T. de Paulis
  • Current opinion in investigational drugs
  • 2007
  • Corpus ID: 35371886
EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist… 
Highly Cited
2006
Highly Cited
2006
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of… 
2006
2006
PIII‐42
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2005
2005
PRX 00023 may reduce symptoms of GAD
  • 2005
  • Corpus ID: 195160372
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)